Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.

By L. Young, F. Wackers, D. Chyun, Janice A. Davey, E. Barrett, R. Taillefer, G. Heller, A. Iskandrian, S. Wittlin, N. Filipchuk and 2 more. Journal of the American Medical Association (JAMA), 2009

850 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/e5cb0b2c0e332d9bff9b3fc018cfdb572b644604

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Hill
2. Dan Ziegler
3. Guanghong Jia
4. J. Sowers
5. V. Basevi
6. James K. Min
7. Warren J. Manning
8. F. Cosentino

In Radiology, Nuclear Medicine and Imaging

1. F. Cosentino
2. Joshua A. Beckman
3. V. Basevi
4. Patricia A. Pellikka
5. M. Creager

Citations in the corpus

• Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity (2018, background): “screening of asymptomatic patients with nuclear imaging does not improve cardiac event rates.(152) Unfortunately, screening approaches including B-type natriuretic peptide, exercise stress testing, and echocardiographic assessment do not seem to be sufficiently sensitive to identify subclinical dysf”
• Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management (2011, background): “In light of recent data [27], generalized and routine screening for CAD in asymptomatic type 2 patients no longer appears to be justified, whereas testing for SMI and silent coronary stenoses should be performed exclusively for individuals at very high risk [49].”
• Standards of Medical Care in Diabetes—2013 (2012, background): “Finally, a recent randomized observational trial demonstrated no clinical benefit to routine screening of asymptomatic patients with type 2 diabetes and normal ECGs (325).”
• Standards of Medical Care in Diabetes—2014 (2013, background): “neuropathy because of its association with mortality risk independent of other cardiovascular risk factors (261,397).”
• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, methodology): “In the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study, 1123 subjects with type 2 diabetes were randomly assigned to adenosine stress radionuclide myocardial perfusion imaging or no screening.(150) Over nearly 5 years of follow-up, there was a cumulative cardiac death or non-fatal myoca”
• Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association (2016, background): “protocol beyond usual diabetes care reduces risk of exercise-induced adverse events in asymptomatic individuals with diabetes (112,113).”
• Exercise and Type 2 Diabetes (2010, neutral): “8 yr did not alter rates of cardiac events (288); thus, the cost-effectiveness and diagnostic value of more intensive testing remains in question.”
• ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, (2011, background): “The difference in the rating for Indication 127 may have been directly affected by publication of the DIAD study (39), which was not available at the time of the RNI ratings.”